Cxbladder for Surveillance
Cxbladder Monitor is a non-invasive genomic urine test that can reduce the burden of repeated cystoscopy in those being monitored for recurrent non-muscle invasive bladder cancer.
Non-compliance. US data highlights the challenge
The need
Patients that have been treated for NMIBC have unique monitoring needs to protect against the threat of recurrence. After assessing a patient’s risk profile, doctors will recommend a regular ongoing schedule of cystoscopies to examine the inside of the bladder and urethra.
The challenge
Recent American Urological Association (AUA) AQUA registry data suggests that the average length of follow-up monitoring among NMIBC patients is 1.8 years. This contrasts to the 5 year AUA surveillance guideline for low risk patients and the ongoing monitoring recommendation for those at higher risk.
The solution
Cxbladder Monitor is a non-invasive genomic urine test that can reduce the burden of repeated cystoscopy in those being monitored for recurrent non-muscle invasive bladder cancer, improving comfort and compliance.
Cxbladder Monitor
A non-invasive test to de-intensify the surveillance of bladder cancer
Combines both genotypic factors and patient clinical information to reliably rule out those patients with a low probability of urothelial cancer, reducing the frequency of cystoscopy required.
Spares patients the discomfort, anxiety, risk, and inconvenience of an invasive procedure.
Improves compliance with scheduled surveillance checks.
Focuses your in-clinic resources on those that need care.
Empowers your team and improve time utilization to maximize overall efficiency.
A non-invasive test to de-intensify the surveillance protocols of NMIBC
Cxbladder Monitor is a non-invasive surveillance alternative that can reduce the burden of repeated cystoscopy in NMIBC patients with a low risk of recurrent disease, improving comfort and compliance.
-
Alternates with cystoscopy to de-intensify surveillance post the most recent diagnosis of urothelial cancer (>9 months).
-
Replaces cystoscopy in patients with no recurrence long term after shared decision making with patient (low risk: 3+ years, high: 5+ years).
- Option of in-home sampling reduces the travel requirement on patients.
Start your Cxbladder journey
Contact our customer service team
Learn more about the Cxbladder suite and how to implement it in your practice.
Featured news
2023 US Patient Survey
In December 2023, 1,507 patients being monitored for recurrent NMIBC were questioned using the Bladder Cancer Advocacy Network’s (BCAN’s) Patient Survey Network.
Surveyed patients were receptive to urine-based testing
80% of patients said having a urine-based surveillance test alternative was moderately to extremely important.
Surveyed patients were then presented with introductory information on Cxbladder Monitor and asked if they would be willing to use the test to reduce the frequency of surveillance cystoscopy - 90% were interested and wanted to learn more.
Optimize your clinical practice while improving the patient experience
The Cxbladder suite helps you prioritize your time and clinical resources on those that need it the most, streamlining practice workflow and increasing overall efficiency.
Cxbladder works for both you and the patient. Spare patients with a low probability of urothelial cancer the discomfort, anxiety and risks of an invasive procedure. With urine-based sampling and the option of in-home sample collection, the Cxbladder suite allows you to optimize your clinical practice while delivering the best patient experience possible.
Cxbladder is a precision test that delivers exceptional performance and clinically actionable results
Cxbladder is an objective test with high sensitivity and NPV.
The Cxbladder suite is supported by an evidence portfolio that includes over 25 peer reviewed publications in leading medical journals.
Cxbladder Triage is now included in the American Urological Association (AUA) Microhematuria Guideline, the first and only UBTM recommended with supporting Level A Evidence.
The Cxbladder suite of tests have been used by over 5,000 urologists in more than 100,000 patients.
How Cxbladder works
The sampling process
Cxbladder's non-invasive urine sampling system is easy for patients to use, streamlining deployment in-clinic.
The science
Cxbladder is an objective test with high sensitivity and NPV that delivers exceptional performance and clinically actionable results. The test works at a molecular level, analyzing biomarker genes to help risk stratify urothelial cancer.
The test report
The Cxbladder test report have been developed in consultation with leading urologists and provides the patient’s Cxbladder score, alongside an interpretation of the results and an assay description.
Start your Cxbladder journey
Contact our customer service team
Learn more about the Cxbladder suite and how to implement it in your practice.
Adopting Cxbladder in your clinic
Implementing Cxbladder
Our team are ready to guide and support you in the deployment and use of Cxbladder. Learn more implementation.
Start your Cxbladder journey
Contact our customer service team to learn more about the Cxbladder suite and how to implement it in your practice.
Cxbladder is available around the world
Cxbladder is available in the United States, and in countries across Asia and South America. Cxbladder is also available in New Zealand, Australia, and Israel.